Virpax Pharmaceuticals Announces Results Of Probudur Dose Escalation Studies
Portfolio Pulse from Benzinga Newsdesk
Virpax Pharmaceuticals has announced the results of dose escalation studies for Probudur. The studies compared Probudur to Exparel, with Probudur demonstrating three to five times longer efficacy than Exparel.

September 27, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Virpax Pharmaceuticals' Probudur has shown superior efficacy to Exparel in dose escalation studies, which could potentially boost the company's stock.
The positive results from the dose escalation studies for Probudur could potentially increase the demand for the drug, leading to increased revenues for Virpax Pharmaceuticals. This could have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100